Developing innovative strategies for advanced transitional cell carcinoma of the bladder.
Several improvements in the treatment of advanced transitional cell malignancies have been provided by clinical trials in the past 10 years. Nonetheless, there are conflicting results regarding the effect of perioperative chemotherapy of muscle-invasive disease and new cytotoxic agents in the metastatic setting. The authors will discuss the results of major clinical trials and examine developing targeted-oriented treatment strategies.
Pollera
Camillo F
CF
Department of Medical Oncology, Presidio Ospedaliero Centrale di Belcolle, ASL di Viterbo, Strada Sammartinese snc, 01100, Viterbo, Italy. cfpollera@oncologiaviterbo.it
Nelli
Fabrizio
F
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D020360:Neoadjuvant Therapy; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D013534:Survival; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology*